<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315182</url>
  </required_header>
  <id_info>
    <org_study_id>MPSIIIB</org_study_id>
    <nct_id>NCT03315182</nct_id>
  </id_info>
  <brief_title>Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB</brief_title>
  <acronym>MPSIIIB</acronym>
  <official_title>Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kevin Flanigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abeona Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, dose-escalation clinical trial of rAAV9.CMV.hNAGLU injected intravenously through
      a peripheral limb vein
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV
      enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter
      inserted into a peripheral limb vein. The vector will be delivered undiluted over 10 to 20
      minutes, under light to moderate sedation as needed. Dosing volume will be approximately 2-5
      mL/kg, depending on final vector product concentration and subject cohort. A tapering course
      of prophylactic enteral prednisolone will be administered.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a dose escalation trial that will begin with the minimal efficacious dose as determined by preclinical studies and approved by the FDA. During the course of the trial, if safety is shown the dose will be escalated according to the clinical protocol.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of safety based on the development of unacceptable toxicity: defined as the occurrence of two or more unanticipated Grade III or higher treatment-related toxicity.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction from baseline values of glycosaminoglycans or their subunit, heparan sulfate, at 6 and/or 12 months after treatment, in any of the following: Cerebrospinal fluid, plasma or urine.</measure>
    <time_frame>6 and/or 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in CSF or plasma NAGLU enzyme activity levels at 6 and/or 12 months</measure>
    <time_frame>6 and/or 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced liver and/or spleen volumes at 6 and/or 12 months after treatment, as measured by magnetic resonance imaging (MRI)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attenuation of brain volume loss as measured by MRI in comparison to natural history data.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved adaptive functioning, or attenuation of decline in adaptive functioning as assessed by parent report using the Vineland Adaptive Behavior Scale</measure>
    <time_frame>6 and/or 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved cognitive ability or attenuation of cognitive deterioration as measured by direct testing of the child using the Leiter International Performance Scale, the Mullen Scales of Early Learning and/or the Sanfilippo Behavior Rating Scale.</measure>
    <time_frame>6 and/or 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Mucopolysaccharidosis Type 3 B</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single infusion:
• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=3 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (High Dose) rAAV9.CMV.hNAGLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single infusion:
• Cohort 2 (High Dose): 5 X 10E13 vg/kg (n=3-6 subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAAV9.CMV.hNAGLU</intervention_name>
    <description>Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein. The vector will be delivered undiluted over 10 to 20 minutes, under light to moderate sedation as needed. Dosing volume will be approximately 2-5 mL/kg, depending on final vector product concentration and subject cohort. A tapering course of prophylactic enteral prednisolone will be administered.</description>
    <arm_group_label>Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU</arm_group_label>
    <arm_group_label>Cohort 2 (High Dose) rAAV9.CMV.hNAGLU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 2 years old or greater

          -  Confirmed diagnosis of MPSIIIB by either of two methods:

               -  No detectable or significantly reduced NaGlu enzyme activity by plasma, serum, or
                  leukocyte assay.

               -  Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations
                  in the NAGLU gene

          -  Clinical history or examination features of neurologic dysfunction

        Exclusion Criteria:

          -  Inability to participate in the clinical evaluation as determined by PI

          -  Identification of two nonsense or null variants on genetic testing of the NAGLU gene,
             as judged by the principal investigator

          -  Has evidence of an attenuated phenotype of MPS IIIB, as judged by the principal
             investigator

          -  Presence of a concomitant medical condition that precludes lumbar puncture or use of
             anesthetics

          -  Inability to be safely sedated in the opinion of the clinical anesthesiologist

          -  Active viral infection based on clinical observations

          -  Concomitant illness or requirement for chronic drug treatment that in the opinion of
             the PI creates unnecessary risks for gene transfer

          -  Subjects with anti-AAV9 antibody titers ≥ 1:100 as determined by ELISA binding
             immunoassay

          -  Serology consistent with exposure to HIV, or serology consistent with active hepatitis
             B or C infection

          -  Bleeding disorder or any other medical condition or circumstance in which a lumbar
             puncture (for collection of CSF) is contraindicated according to local institutional
             policy

          -  Visual or hearing impairment sufficient to preclude cooperation with
             neurodevelopmental testing

          -  Uncontrolled seizure disorder, due to the requirement for multiple MRI examinations as
             part of the study protocol. Subjects who are stable on anticonvulsive medications may
             be included

          -  Any item (braces, etc.) which would exclude the patient from being able to undergo MRI
             according to local institutional policy

          -  Any other situation that would exclude the patient from undergoing any other procedure
             required in this study

          -  Patients with cardiomyopathy or significant congenital heart abnormalities

          -  The presence of significant non-MPS IlIB related CNS impairment or behavioral
             disturbances that would confound the scientific rigor or interpretation of results of
             the study

          -  Abnormal laboratory values based upon local institutional normal

          -  Female participant who is pregnant or demonstrates a positive urine or Beta-hCG result
             at screening assessment (if applicable).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Flanigan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federica Rinaldi</last_name>
    <phone>614-355-2897</phone>
    <email>federica.rinaldi@nationwidechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tabatha Simmons, PhD</last_name>
    <phone>614-722-6921</phone>
    <email>tabatha.simmons@nationwidechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther. 2011 Jun;19(6):1025-33. doi: 10.1038/mt.2011.34. Epub 2011 Mar 8.</citation>
    <PMID>21386820</PMID>
  </reference>
  <reference>
    <citation>Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov;119(3):239-248. doi: 10.1016/j.ymgme.2016.08.002. Epub 2016 Aug 18.</citation>
    <PMID>27590925</PMID>
  </reference>
  <reference>
    <citation>Neufeld EF, Cantz MJ. Corrective factors for inborn errors of mucopolysaccharide metabolism. Ann N Y Acad Sci. 1971 Jul 6;179:580-7.</citation>
    <PMID>4255108</PMID>
  </reference>
  <reference>
    <citation>Weber B, Guo XH, Kleijer WJ, van de Kamp JJ, Poorthuis BJ, Hopwood JJ. Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet. 1999 Jan;7(1):34-44.</citation>
    <PMID>10094189</PMID>
  </reference>
  <reference>
    <citation>Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr. 2013 May;102(5):462-70. doi: 10.1111/apa.12169. Epub 2013 Feb 6. Review.</citation>
    <PMID>23336697</PMID>
  </reference>
  <reference>
    <citation>de Ruijter J, Valstar MJ, Wijburg FA. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. Curr Pharm Biotechnol. 2011 Jun;12(6):923-30. doi: 1389-2010/11 $58.00+.00. Review.</citation>
    <PMID>21235449</PMID>
  </reference>
  <reference>
    <citation>Murrey DA, Naughton BJ, Duncan FJ, Meadows AS, Ware TA, Campbell KJ, Bremer WG, Walker CM, Goodchild L, Bolon B, La Perle K, Flanigan KM, McBride KL, McCarty DM, Fu H. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev. 2014 Jun;25(2):72-84. doi: 10.1089/humc.2013.208. Epub 2014 Apr 10.</citation>
    <PMID>24720466</PMID>
  </reference>
  <reference>
    <citation>Ribera A, Haurigot V, Garcia M, Marcó S, Motas S, Villacampa P, Maggioni L, León X, Molas M, Sánchez V, Muñoz S, Leborgne C, Moll X, Pumarola M, Mingozzi F, Ruberte J, Añor S, Bosch F. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. Hum Mol Genet. 2015 Apr 1;24(7):2078-95. doi: 10.1093/hmg/ddu727. Epub 2014 Dec 18.</citation>
    <PMID>25524704</PMID>
  </reference>
  <reference>
    <citation>Hamano K, Hayashi M, Shioda K, Fukatsu R, Mizutani S. Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue. Acta Neuropathol. 2008 May;115(5):547-59. Epub 2007 Dec 4.</citation>
    <PMID>18060551</PMID>
  </reference>
  <reference>
    <citation>Tamagawa K, Morimatsu Y, Fujisawa K, Hara A, Taketomi T. Neuropathological study and chemico-pathological correlation in sibling cases of Sanfilippo syndrome type B. Brain Dev. 1985;7(6):599-609.</citation>
    <PMID>3938624</PMID>
  </reference>
  <reference>
    <citation>Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther. 2011 Aug;11(4):321-30. Review.</citation>
    <PMID>21557723</PMID>
  </reference>
  <reference>
    <citation>Saeki I, Tokunaga S, Matsuura T, Hayashida M, Yanagi Y, Taguchi T. A formula for determining the standard liver volume in children: a special reference for neonates and infants. Pediatr Transplant. 2012 May;16(3):244-9. doi: 10.1111/j.1399-3046.2011.01624.x. Epub 2011 Dec 12.</citation>
    <PMID>22151603</PMID>
  </reference>
  <reference>
    <citation>Schlesinger AE, Edgar KA, Boxer LA. Volume of the spleen in children as measured on CT scans: normal standards as a function of body weight. AJR Am J Roentgenol. 1993 May;160(5):1107-9.</citation>
    <PMID>8470587</PMID>
  </reference>
  <reference>
    <citation>Malm G, Månsson JE. Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Paediatr. 2010 Aug;99(8):1253-7. doi: 10.1111/j.1651-2227.2010.01800.x. Epub 2010 Mar 14.</citation>
    <PMID>20337777</PMID>
  </reference>
  <reference>
    <citation>Dale DC, Fauci AS, Guerry D IV, Wolff SM. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest. 1975 Oct;56(4):808-13.</citation>
    <PMID>1159089</PMID>
  </reference>
  <reference>
    <citation>Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. Trends Immunol. 2010 Aug;31(8):318-24. doi: 10.1016/j.it.2010.05.006. Review.</citation>
    <PMID>20620114</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Kevin Flanigan</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>MPS IIIB</keyword>
  <keyword>Sanfilippo Syndrome B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis III</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

